onda

BOARD OF DIRECTORS

The Board of Directors (BoD) runs the general affairs and represents the VPH Institute in all circumstances. Its main duty is to drive the Institute policy, setting the agendas, proposing specific actions and approving the annual business plan.

The current Board of Directors is composed by the representatives of the supporting members, eleven prestigious organisations that excel worldwide for their research quality and their focus on in silico medicine.
  • Prof Liesbet Geris

    Executive Director

    Prof.Liesbet Geris

    Universities of Liège and KUL – Leuven (Belgium)

  • Rossana Alessandrello

    Director

    Rossana Alessandrello

    Agència de Qualitat i Avaluació Sanitàries de Catalunya - AQuAS (Spain)

  • Prof.Ilse Jonkers

    Director

    Prof.Ilse Jonkers

    KULeuven (Belgium)

  • Dr. Irene Vignon-Clementel

    Director

    Dr. Irene Vignon-Clementel

    Inria (France)

  • Prof. Reinhard Schneider

    Director

    Prof. Reinhard Schneider

    Luxembourg Centre for Systems Biomedicine (Luxembourg)

  • Prof.Leif Rune Hellevik

    Director

    Prof.Leif Rune Hellevik

    Norwegian University of Science and Technology (Norway)

  • Prof.Alfons Hoekstra

    Director

    Prof.Alfons Hoekstra

    University of Amsterdam (Netherlands)

  • Prof.Merryn Tawhai

    Director

    Prof.Merryn Tawhai

    University of Auckland (New Zealand)

  • Prof.Marco Viceconti

    Director

    Prof.Marco Viceconti

    University of Bologna (Italy)

  • Dr.Claudio Capelli

    Director

    Dr.Claudio Capelli

    UCL Institute of Cardiovascular Science / Great Ormond Street Hospital for Children (United Kingdom)

  • Prof.Damien Lacroix

    Director

    Prof.Damien Lacroix

    University of Sheffield (United Kingdom)

  • Prof.Francesco Pappalardo

    Director

    Prof.Francesco Pappalardo

    University of Catania (Italy)

History of Directors >

News

  • 05/11/2024

    "In silico trials: an updated SWOT Analysis" released by In Silico World

    • The document comprehensively examines the strengths, weaknesses, opportunities, and threats for In Silico Trials in healthcare, providing a roadmap to help biomedical companies navigate and adopt these innovative methodologies. -Read more-
  • 31/10/2024

    In the literature: October 2024 highlights

    • Click here to read some interesting recently published papers from our community. If you have published an article in the field of in silico medicine, send it to us: we will include it in this section of the newsletter! -Read more-
  • 31/10/2024

    Joint motion for a resolution to revise the Medical Devices Regulation

    • The European Parliament has voted with a large majority to urge the European Commission to implement critical amendments to the EU Medical Device Regulation (MDR) by the first quarter of 2025. The drive for reform is intended to tackle pressing issues in the regulation, which has been criticised for its excessive bureaucracy and impact on patient care, jobs, and innovation in the medical device sector. -Read more-
  • 31/10/2024

    EU Budget for 2025 Prioritizes Research, Health, Education, and Climate Action

    • The European Parliament has presented their draft budget demanding an EU budget for 2025 that focuses on improving people's lives, boosting competitiveness, and addressing current challenges. MEPs are proposing a budget of nearly €201 billion, which exceeds the European Commission's initial proposal of around €199.76 billion. -Read more-
More news

Events

More events
newsletter

Subscribe to the VPH Institute Newsletter

ARCHIVE

Read all the newsletters of the VPH Institute

GO